Opioid

Three Years Since Inception, CNX Foundation and Mentorship Academy Build on Success Addressing Region's Complex Societal Challenges

Retrieved on: 
Wednesday, February 21, 2024
Steps, Investment, Working poor, CNX, Survivor, Student, Opioid, Growth, Food, CCAC, Parent, Hope, Hunger, Expansion, Employment, Domestic violence, Knowledge, Veteran, Community college, Workforce, Tangibility, Partnership, Cryptocurrency

PITTSBURGH, Feb. 21, 2024 /PRNewswire/ -- Building on the CNX Foundation and Mentorship Academy's record of success in making a substantive difference on the complex issues facing the region, CNX's (NYSE: CNX) Board of Directors and Nick Deiuliis, President and CEO of the Company, today announced that the Board approved Mr. Deiuliis' request to make a $1.5 million donation to the CNX Foundation and commensurately reduce his 2024 compensation.

Key Points: 
  • This follows a previous $1.5 million contribution in 2023 and $1 million contribution in 2022 to the CNX Foundation funded through continuing reductions in Mr. Deiuliis' compensation.
  • Mr. Deiuliis continued, "We said when we created the CNX Foundation that the approach would target community investments that are Tangible, Impactful, and Local.
  • So, I am happy to help fund the expansion of the successful efforts of the CNX Foundation in a way where it is most beneficial to the region and to the shareholder owners of CNX."
  • To learn more about the Mentorship Academy and apply to enroll in the program, visit https://www.cnx.com/about-us/the_mentorship-academy .

Studies Explore: Semaglutide Use and Its Impact on Total Hip Arthroplasty Postoperative Outcomes

Retrieved on: 
Monday, February 12, 2024
Facial muscles, Diabetes, SAN, Pulmonary embolism, Barnes-Jewish Hospital, Infection, Shock, MD, Obesity, Wound healing, Weight loss, Female, Osteopenia, Deep vein thrombosis, Respiratory failure, Risk, Type 2 diabetes, Attention, BMI, THA, Pearl, Patient, MPH, Opioid, Interview, Mortality, AAOS, Medicine, Long School, American Academy, Dentistry

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Ozempic and Wegovy, which both contain the active ingredient semaglutide, have received recent attention in the media and on social platforms for its effectiveness in supporting weight loss. Ozempic, which is approved for people with Type 2 diabetes, has now become a widely accepted choice for weight loss, and Wegovy was approved in 2021 for long-term weight management.

Key Points: 
  • As the use of semaglutide increases among patients for diabetes and/or weight management, it's important to understand how it can impact postoperative outcomes of joint replacement surgery.
  • Two studies presented at the AAOS 2024 Annual Meeting looked at the use of semaglutide and its impact on outcomes of total hip arthroplasty (THA), finding that patients who take semaglutide at the time of THA experience similar postoperative outcomes to those who do not take the drug.
  • The researchers found that postoperative complications after THA are similar between obese patients using semaglutide compared to those who did not.
  • Both cohorts experienced a similar risk of hip arthroplasty revision, prosthesis infection, opioid-related disorders, surgical site infections, mortality, respiratory failure, pulmonary embolism, deep vein thrombosis, postoperative dehydration, cardiovascular comorbidities, shock, and prosthesis dislocations.

Ibogaine By David Dardashti Makes Statement on Public Concerns Regarding Fentanyl Distribution

Retrieved on: 
Sunday, February 11, 2024
Human, Opioid, Heroin, Drug

Miami, Feb. 10, 2024 (GLOBE NEWSWIRE) -- In light of the rising threat of fentanyl distribution in the United States and its ties to China's massive debts, Ibogaine By David Dardashti, a leader in addiction recovery treatment, today released a statement on their position.

Key Points: 
  • Miami, Feb. 10, 2024 (GLOBE NEWSWIRE) -- In light of the rising threat of fentanyl distribution in the United States and its ties to China's massive debts, Ibogaine By David Dardashti, a leader in addiction recovery treatment, today released a statement on their position.
  • "It is clear that something needs to be done," says David Dardashti, owner of Ibogaine By David Dardashti.
  • "The rising level of fentanyl distribution is a real threat to our communities, one we can no longer ignore.
  • Ibogaine By David Dardashti Offers Holistic Healing by utilizing unique treatment for every condition being treated.

ZeOmega Named Best in KLAS® for Payer Care Management Solutions in 2024

Retrieved on: 
Wednesday, February 7, 2024
AI, Feedback, Research, Opioid, Product innovation, Information technology, Longevity, Organization, Table tennis rubber, Microsoft, Culture, Trust

PLANO, Texas, Feb. 7, 2024 /PRNewswire/ -- ZeOmega®, the industry's leading population health management organization, announced today that it was named Best in KLAS for Payer Care Management Solutions for the third consecutive year, as featured in the just-released 2024 Best in KLAS: Software & Services Report. This honor from KLAS Research comes on the heels of ZeOmega's tremendous momentum throughout 2023, with record growth, 94% client retention, excellent customer satisfaction, and an impressive new set of features and functionalities.

Key Points: 
  • #1 Ranking Follows Company's Record Growth in 2023, Distinguished by Unmatched Customer Satisfaction, Retention, and Product Innovation
    PLANO, Texas, Feb. 7, 2024 /PRNewswire/ -- ZeOmega ®, the industry's leading population health management organization, announced today that it was named Best in KLAS for Payer Care Management Solutions for the third consecutive year, as featured in the just-released 2024 Best in KLAS: Software & Services Report .
  • ZeOmega's Best in KLAS ranking reflects the company's continued dominance in the care management market segment.
  • In addition to being ranked Best in KLAS for Payer Care Management Solutions in 2023 and 2022 , the company was recognized as a top performer in the Payer Care Management 2023 Report .
  • ZeOmega will be formally honored at the KLAS Awards Show at HIMSS on March 11, 2024, in Orlando, Florida.

Ibogaine By David Dardashti Offers Free Online Support for Post-Treatment Care

Retrieved on: 
Tuesday, February 6, 2024
DSM-IV codes, PTSD, Ibogaine, Opioid, Depression, Life, Senior counsel

To help those who have already completed treatment, Ibogaine By David Dardashti is now offering free online support for those in need.

Key Points: 
  • To help those who have already completed treatment, Ibogaine By David Dardashti is now offering free online support for those in need.
  • “At Ibogaine By David Dardashti, we strive to provide the highest level of care and nurturing to those who are fighting addiction or mental health issues,” said Dr. David Dardashti.
  • That’s why we’ve implemented this free online support program.” The free online support program will provide clients with counseling and support in the months following treatment.
  • Ibogaine By David Dardashti encourages anyone who has recently completed treatment to take advantage of their free online support program.

Study Highlights Outcomes of New Jersey's 2017 Opioid Legislation

Retrieved on: 
Tuesday, January 30, 2024
Emergency department, FACEP, Opioid, Legislation, Cognitive behavioral therapy, Research, Prohibition, MD, Prescription, Government, Morristown Medical Center, Patient, Pain, Brandeis University, FACP, Emergency medicine, Partnership, Injury, MBA, Trauma, Communication, Pain management, Education, Associate, Advertising, Organization

Millburn, NJ, Jan. 30, 2024 (GLOBE NEWSWIRE) -- A recent study conducted at Morristown Medical Center, titled "New legislation in New Jersey reduced opioid use among trauma patients," provides an analysis of the effects of New Jersey's 2017 opioid legislation.

Key Points: 
  • Millburn, NJ, Jan. 30, 2024 (GLOBE NEWSWIRE) -- A recent study conducted at Morristown Medical Center, titled "New legislation in New Jersey reduced opioid use among trauma patients," provides an analysis of the effects of New Jersey's 2017 opioid legislation.
  • This change was based on evidence suggesting the potential for opioid dependency within a short period of initial use.
  • Findings from the Morristown Medical Center study indicate a correlation between the new law and a change in opioid prescription patterns.
  • "The findings from these studies provide insights into the impact of New Jersey's 2017 opioid legislation,” said Angelo Valente, Executive Director of PDFNJ.

Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, ARCH Venture Partners, Senior, Corporation, GSK plc, MedImmune, Takeda Pharmaceutical Company, Knowledge, Eli Lilly and Company, Opioid, WRF, VBI Vaccines, AstraZeneca, Acquisition, Development, Epilepsy, Public, Growth, General counsel, Vilya, Corporate development, Patient, Venture round, LP, Research, Trial of the century, ARCH, Therapy, DSM-IV codes, Series

PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.

Key Points: 
  • PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.
  • In conjunction with the Series B financing, Proniras has appointed Steven Gillis, Ph.D., as Chairman and Atul Saran as an independent member to the Company’s Board of Directors.
  • "Their wealth of knowledge and industry experience will be instrumental in guiding Proniras through its next phase of growth.
  • We look forward to their leadership and contributions as we continue to advance Proniras through the next stages of product development."

LONG ISLAND UNIVERSITY TO HONOR 16 LAUREATES IN CELEBRATION OF THE 75TH ANNIVERSARY OF ITS GEORGE POLK AWARDS IN JOURNALISM

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Multimedia, Long Island University, The Washington Post, CNN, Survival, COVID-19, ProPublica, Digital media, Associated, Civil rights movement, Bloodshed, AI, Opioid, Cipriani S.A., News, Politics, George Polk Awards, NSA, The New Yorker, Sackler family, Communication, Associated Press, Lenin's Mausoleum, Global health, Infection, CBS, This American Life, The Philadelphia Inquirer, Journalism, CBS News, Citizenfour, Culture, Watergate scandal, Beauty, Human rights movement, The Wall Street Journal, American Life, Disinformation, Film industry

BROOKVILLE, N.Y., Jan. 31, 2024 /PRNewswire/ -- Long Island University today announced it will mark the 75th anniversary of its George Polk Awards in journalism by honoring 16 individuals whose careers reflect the awards' commitment to outstanding investigative reporting as the first-ever Polk Laureates.

Key Points: 
  • BROOKVILLE, N.Y., Jan. 31, 2024 /PRNewswire/ -- Long Island University today announced it will mark the 75th anniversary of its George Polk Awards in journalism by honoring 16 individuals whose careers reflect the awards' commitment to outstanding investigative reporting as the first-ever Polk Laureates.
  • The event, to be held at Cipriani 42nd Street will be hosted by CNN anchor and CBS 60 Minutes correspondent Anderson Cooper.
  • The Polk Awards were established in 1949 by Long Island University to commemorate George Polk, a CBS correspondent murdered in 1948 while covering the Greek civil war.
  • "Long Island University has long recognized the importance of investigative journalism through the George Polk Awards and our George Polk School of Communications which is helping prepare an international class of the journalists of tomorrow," noted Dr. Kimberly Cline, President of Long Island University.

Voices for Non-Opioid Choices Coalition Applauds Introduction of Legislation to Expand Access to Non-Opioid Pain Management Options for Seniors

Retrieved on: 
Tuesday, January 30, 2024
Congress, Alternatives, Medicare Part D, Opioid, Patient, Pain, FDA, Pharmacy, Addiction, Voices, Medicare

WASHINGTON, Jan. 30, 2024 /PRNewswire/ -- Today, Congress took a crucial step forward in the fight to prevent opioid addiction by introducing the bipartisan Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. Championed by Representative Mariannette Miller-Meeks (R-IA) and Representative Tony Cárdenas (D-CA), the Alternatives to PAIN Act will prevent unnecessary exposure to opioids and open up access to innovative pain management therapies for American seniors.

Key Points: 
  • Championed by Representative Mariannette Miller-Meeks (R-IA) and Representative Tony Cárdenas (D-CA), the Alternatives to PAIN Act will prevent unnecessary exposure to opioids and open up access to innovative pain management therapies for American seniors.
  • "In order to save lives, the Alternatives to PAIN Act will ensure that seniors will have access to the full range of pain treatment modalities."
  • The NOPAIN Act expands patient and provider access to FDA-approved non-opioid pain management approaches in outpatient surgical settings beginning in 2025.
  • The Alternatives to PAIN Act builds on this by ensuring access to non-opioid approaches at the pharmacy counter.

Gallus Medical Detox Centers Announces 2023 Patient Results

Retrieved on: 
Friday, January 19, 2024
Health, Opioid, Patient, Feedback, Child, LPC, Pharmaceutical industry

Gallus medical detox maintained and enhanced their medical and patient treatment protocols, including their Accelerated Micro Induction Detox Protocol for the treatment of Fentanyl and Synthetic Opioid addiction.

Key Points: 
  • Denver,  Colorado--(Newsfile Corp. - January 18, 2024) - Gallus Medical Detox, a provider of inpatient medical detoxification services for patients struggling with severe drug and alcohol addictions, is pleased to announce 2023 was another successful year for treating patients with over 750 admissions for the year.
  • Under the leadership of Dr. Ronald Sierzenski, Chief Medical Officer, Taryn Olivera RN-BSN, Chief Nursing Officer, and Sara Kaylor, LCDC, LPC, Executive Clinical Director, Gallus Medical Detox maintained and enhanced their medical and patient treatment protocols, including their Accelerated Micro Induction Detox Protocol for the treatment of Fentanyl and Synthetic Opioid addiction.
  • Warren Olsen, Chairman and CEO, stated, "Since our founding in 2011, we have treated thousands of patients with consistently positive results and feedback.
  • 2023 was another incredible year for our treatment results as we continued our unwavering commitment to providing the highest quality patient care."